Figure 4.

Leukemic blasts differentiate into pDCs in vivo. (A-B) BM cells were harvested from the primary NSG mice receiving pDC-AML leukemic cells, as described in supplemental Figure 4 and supplemental Table 6. The unsorted BM cells, purified leukemic blasts, and purified pDCs were injected IV into secondary NSG mice. Engraftment of human CD45⁺ cells was evaluated from peripheral blood 4 weeks (A) and 8 weeks (B) after transplant. (C) pDC-AML phenotype in the secondary NSG mice receiving purified leukemic blasts. Data are mean ± SD. (D-E) Representative flow plots showing hCD45⁺ cells in the secondary NSG mice receiving purified blasts (D) or pDCs (E). (F) Representative flow plot showing pDC-AML phenotype in hCD45⁺ cells from panel D. ***P < .001.